<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03259516</url>
  </required_header>
  <id_info>
    <org_study_id>18/17-n</org_study_id>
    <nct_id>NCT03259516</nct_id>
  </id_info>
  <brief_title>Nivolumab With Chemotherapy in Refractory MDS</brief_title>
  <official_title>Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence of involvement of checkpoint pathways, including PD-1, in the pathogenesis
      and resistance of myelodysplastic syndrome (MDS). However monotherapy with checkpoint
      inhibitors was ineffective in a number of studies, indicating the presence of several
      mechanisms of resistance. This pilot study evaluates the safety and preliminary efficacy of
      nivolumab combination with currently existing treatments in MDS patients who failed at least
      one line of therapy. The study evaluates if there is a combination which induces objective
      responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response rate (ORR) defined as complete response plus partial response (CR + PR) and hematological improvement (HI). MDS International Working Group criteria will be used to assess response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>6 months</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of severe bacterial, fungal and viral infections incidence based on laboratory confirmation and attending physician assessment</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Nivo + FC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo + LDAC + ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo + LDAC + Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo + Melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivo + 5-aza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>1 mg/kg by vein on Days 1 and 15 of a 28 day cycle</description>
    <arm_group_label>Nivo + FC</arm_group_label>
    <arm_group_label>Nivo + LDAC + ATRA</arm_group_label>
    <arm_group_label>Nivo + LDAC + Sildenafil</arm_group_label>
    <arm_group_label>Nivo + Melphalan</arm_group_label>
    <arm_group_label>Nivo + 5-aza</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle</description>
    <arm_group_label>Nivo + 5-aza</arm_group_label>
    <other_name>5-azacitidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.</description>
    <arm_group_label>Nivo + FC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.</description>
    <arm_group_label>Nivo + FC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle</description>
    <arm_group_label>Nivo + LDAC + ATRA</arm_group_label>
    <arm_group_label>Nivo + LDAC + Sildenafil</arm_group_label>
    <other_name>Ara-C, LDAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>all trans retinoic acid</intervention_name>
    <description>45 mg/m2 per os daily during the whole course of treatment</description>
    <arm_group_label>Nivo + LDAC + ATRA</arm_group_label>
    <other_name>ATRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>20 mg per os three times a day during the whole course of treatment</description>
    <arm_group_label>Nivo + LDAC + Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>2 mg per os daily during the whole course of treatment</description>
    <arm_group_label>Nivo + Melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with myelodysplastic syndrome (MDS) (up to 20% blasts) of any risk. Patients
             with lower risk MDS (low and int-1 by IPSS) should have failed prior
             non-hypomethylating agent therapy (ie growth factors or lenalidomide). Patients with
             higher risk MDS (int-2 or high by IPSS) should have failed prior at least one therapy
             with a hypomethylating agent or Ara-C.

          -  Age 18 years or older.

          -  No severe organ dysfunction: creatinine &lt;=2.5 x ULN; serum bilirubin &lt;=2.5 x ULN; AST
             and ALT &lt;=5 x ULN.

          -  Karnofsky index &gt;=70%

          -  Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotrophin (beta-hCG) pregnancy test result within 24 hours prior to the
             first dose of treatment and must agree to use an effective contraception to avoid
             pregnancy for 24 weeks

          -  Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 24 weeks after the last dose of
             nivolumab.

        Exclusion Criteria:

          -  Another malignancy requiring treatment at the time of inclusion

          -  History of interstitial lung disease or pneumonitis

          -  Patients with any other known concurrent severe and/or uncontrolled medical condition
             (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure
             NYHA Class III or IV, myocardial infarction within 6 months, and poorly controlled
             hypertension; chronic renal failure; or active uncontrolled infection) which, in the
             opinion of the investigator could compromise participation in the study

          -  Active, known or suspected autoimmune disease requiring treatment at the time of
             inclusion

          -  Pregnancy or breastfeeding

          -  Patients unwilling or unable to comply with the protocol

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent

          -  Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivan S Moiseev, MD, PhD</last_name>
    <phone>+79217961951</phone>
    <email>moisiv@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena V Morozova, MD, PhD</last_name>
    <phone>+79119278229</phone>
    <email>dr_morozova@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan S. Moiseev, MD, PhD</last_name>
      <phone>+79217961951</phone>
      <email>moisiv@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Elena V Morozova, MD, PhD</last_name>
      <phone>+79119278229</phone>
      <email>dr_morozova@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Boris V Afanasyev, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena V Morozova, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yulia V Rudnizkaya, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan S Moiseev, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolai Yu Tcvetkov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>nivolumab</keyword>
  <keyword>5-azacitidine</keyword>
  <keyword>cytarabine</keyword>
  <keyword>melphalan</keyword>
  <keyword>all-trans retinoic acid</keyword>
  <keyword>lymphodepletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

